Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Hormones and Bone Tissue01:17

Hormones and Bone Tissue

3.6K
The endocrine system produces and secretes hormones, which interact with the skeletal system. These hormones control bone growth, maintain bone once it is formed, and remodel it.
Hormones That Influence Osteoblasts and/or Maintain the Matrix
Several hormones are necessary for controlling bone growth and maintaining the bone matrix. The pituitary gland secretes growth hormone (GH), which, as its name implies, controls bone growth. This happens in several ways: first, it triggers chondrocyte...
3.6K
Bone Remodeling01:40

Bone Remodeling

40.2K
Bone remodeling is a continuous and balanced process of bone resorption by osteoclasts and bone formation by osteoblasts. In adults, it helps maintain bone mass and calcium homeostasis. While mechanical stress can stimulate turnover as part of the normal maintenance and reparative process, several hormones also regulate bone remodeling.
40.2K
Osteoclasts in Bone Remodeling01:31

Osteoclasts in Bone Remodeling

3.9K
Osteoclasts are cells responsible for bone resorption and remodeling. They originate from hematopoietic progenitor cells present in the bone marrow. Numerous progenitor cells fuse to form multinucleated cells, each with 10-20 nuclei. A single osteoclast has a diameter of 150 to 200 µM. These cells have ruffled borders that break down the underlying bone tissue and release minerals such as calcium into the blood in bone resorption. Osteoclasts cling to bones with their ruffled edges during...
3.9K
Bone Disorders01:29

Bone Disorders

5.0K
Aging and its effect on bone remodeling is the most common cause of bone disorders. In young and healthy people, bone deposition and resorption happen at an equal rate to maintain optimal bone health.
Bone deposition is also affected by the levels of sex hormones like estrogen and testosterone that promote osteoblast activity and bone matrix synthesis. When the level of these hormones decreases due to aging, it causes a reduction in bone deposition. As a result, bone resorption by osteoclasts...
5.0K
Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

2.8K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
2.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Incidentally discovered, intentionally managed: a narrative review of the last decade's updates on the management of neuroendocrine tumor of the appendix.

Annals of gastroenterology·2026
Same authorSame journal

The metabolic effects of glucocorticoid replacement therapy in patients with secondary adrenal insufficiency due to hypothalamic-pituitary diseases: results from a retrospective and longitudinal study.

Pituitary·2026
Same author

Clinical Exome Sequencing Study in a Cohort of Growth Hormone-Secreting Pituitary Adenomas.

Endocrine, metabolic & immune disorders drug targets·2026
Same author

A Four-Week Treatment With Dapagliflozin Is Associated With a Reduction in Insulin-Stimulated Renal Cortical Glucose Uptake: A Post Hoc Analysis From a Pilot Study.

Diabetes, obesity & metabolism·2026
Same author

Proteomic profile of bone in patients with acromegaly: new insights from a pilot exploratory study.

Journal of endocrinological investigation·2026
Same author

Primary adrenal insufficiency induced by immune checkpoint inhibitors (ICIs): a case series and systematic literature review.

Reviews in endocrine & metabolic disorders·2026

Related Experiment Video

Updated: Jan 12, 2026

Author Spotlight: Exploring the Impact of Lingnan Fire-Needle Therapy in Osteoporosis Intervention
03:56

Author Spotlight: Exploring the Impact of Lingnan Fire-Needle Therapy in Osteoporosis Intervention

Published on: April 26, 2024

1.2K

Acromegaly treatment and bone: a bidirectional relationship.

Sabrina Chiloiro1,2, Chiara Palumbo3,4, Antonella Giampietro3,4

  • 1School of Medicine and Surgery, Università Cattolica del Sacro Cuore, Rome, Italy. sabrina.chiloiro@unicatt.it.

Pituitary
|November 8, 2025
PubMed
Summary

Acromegaly patients have higher vertebral fracture risks due to excess growth hormone (GH) and insulin-like growth factor I (IGF-I). Somatostatin receptor ligands may reduce fracture incidence and impact bone metabolism.

Keywords:
AcromegalyBoneFirst generations somatostatin receptor ligands (octreotide, lanreotide)GHGH receptor antagonist (pegvisomant)IGF-ISecond generation somatostatin receptor ligands (pasireotide)Vertebral fractures

More Related Videos

Computed Tomography and Optical Imaging of Osteogenesis-angiogenesis Coupling to Assess Integration of Cranial Bone Autografts and Allografts
13:16

Computed Tomography and Optical Imaging of Osteogenesis-angiogenesis Coupling to Assess Integration of Cranial Bone Autografts and Allografts

Published on: December 22, 2015

11.9K
Author Spotlight: Developing a Rat Model for Weight-Bearing Intervention to Investigate Osteonecrosis of the Femoral Head
05:55

Author Spotlight: Developing a Rat Model for Weight-Bearing Intervention to Investigate Osteonecrosis of the Femoral Head

Published on: September 27, 2024

901

Related Experiment Videos

Last Updated: Jan 12, 2026

Author Spotlight: Exploring the Impact of Lingnan Fire-Needle Therapy in Osteoporosis Intervention
03:56

Author Spotlight: Exploring the Impact of Lingnan Fire-Needle Therapy in Osteoporosis Intervention

Published on: April 26, 2024

1.2K
Computed Tomography and Optical Imaging of Osteogenesis-angiogenesis Coupling to Assess Integration of Cranial Bone Autografts and Allografts
13:16

Computed Tomography and Optical Imaging of Osteogenesis-angiogenesis Coupling to Assess Integration of Cranial Bone Autografts and Allografts

Published on: December 22, 2015

11.9K
Author Spotlight: Developing a Rat Model for Weight-Bearing Intervention to Investigate Osteonecrosis of the Femoral Head
05:55

Author Spotlight: Developing a Rat Model for Weight-Bearing Intervention to Investigate Osteonecrosis of the Femoral Head

Published on: September 27, 2024

901

Area of Science:

  • Endocrinology
  • Bone Metabolism
  • Pharmacology

Background:

  • Acromegaly results from excess growth hormone (GH) and insulin-like growth factor I (IGF-I) secretion.
  • Excess GH and IGF-I lead to systemic complications, including increased risk of fragility vertebral fractures (VFs).
  • Long-term exposure to high GH/IGF-I levels is a known risk factor for fractures in acromegaly.

Purpose of the Study:

  • To review the incidence of vertebral fractures (VFs) in acromegaly patients treated with GH/IGF-I-lowering drugs.
  • To explore the potential effects of these treatments on bone metabolism.
  • To summarize preclinical data on molecular interactions between GH/IGF-I-lowering drugs and bone.

Main Methods:

  • Literature review of studies on vertebral fracture incidence in acromegaly.
  • Analysis of data on the impact of GH/IGF-I-lowering drugs on bone metabolism.
  • Inclusion of preclinical data on molecular pathways.

Main Results:

  • First- and second-generation somatostatin receptor ligands (SRLs) have shown reduced incidence of vertebral fractures (i-VFs).
  • Direct effects of SRLs on bone metabolism are not yet fully reported.
  • Preclinical data may elucidate molecular mechanisms linking these drugs to bone health.

Conclusions:

  • GH/IGF-I-lowering drugs, particularly SRLs, appear to reduce vertebral fracture incidence in acromegaly.
  • Further research is needed to understand the direct impact of these therapies on bone metabolism and related molecular pathways.